JP2023543924A5 - - Google Patents

Info

Publication number
JP2023543924A5
JP2023543924A5 JP2023520459A JP2023520459A JP2023543924A5 JP 2023543924 A5 JP2023543924 A5 JP 2023543924A5 JP 2023520459 A JP2023520459 A JP 2023520459A JP 2023520459 A JP2023520459 A JP 2023520459A JP 2023543924 A5 JP2023543924 A5 JP 2023543924A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
formula
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023520459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543924A (ja
JP7793614B2 (ja
Filing date
Publication date
Priority claimed from GBGB2015585.9A external-priority patent/GB202015585D0/en
Application filed filed Critical
Publication of JP2023543924A publication Critical patent/JP2023543924A/ja
Publication of JP2023543924A5 publication Critical patent/JP2023543924A5/ja
Application granted granted Critical
Publication of JP7793614B2 publication Critical patent/JP7793614B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023520459A 2020-10-01 2021-09-30 チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのampkアゴニストとしての使用 Active JP7793614B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2015585.9A GB202015585D0 (en) 2020-10-01 2020-10-01 New compounds
GB2015585.9 2020-10-01
PCT/GB2021/052535 WO2022069894A1 (en) 2020-10-01 2021-09-30 Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders

Publications (3)

Publication Number Publication Date
JP2023543924A JP2023543924A (ja) 2023-10-18
JP2023543924A5 true JP2023543924A5 (cg-RX-API-DMAC7.html) 2024-10-04
JP7793614B2 JP7793614B2 (ja) 2026-01-05

Family

ID=73223766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520459A Active JP7793614B2 (ja) 2020-10-01 2021-09-30 チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのampkアゴニストとしての使用

Country Status (13)

Country Link
US (1) US12643918B2 (cg-RX-API-DMAC7.html)
EP (1) EP4222147B1 (cg-RX-API-DMAC7.html)
JP (1) JP7793614B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079163A (cg-RX-API-DMAC7.html)
CN (1) CN116368141B (cg-RX-API-DMAC7.html)
AU (1) AU2021352146A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193947A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018732T3 (cg-RX-API-DMAC7.html)
GB (1) GB202015585D0 (cg-RX-API-DMAC7.html)
HU (1) HUE071685T2 (cg-RX-API-DMAC7.html)
MX (1) MX2023003825A (cg-RX-API-DMAC7.html)
PL (1) PL4222147T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022069894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202112529D0 (en) * 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
JPWO2024075784A1 (cg-RX-API-DMAC7.html) * 2022-10-05 2024-04-11

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010270030B2 (en) 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
GB201915094D0 (en) 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
CN122421964A (zh) 2023-07-20 2026-07-17 塔吉农有限责任公司 使用双重ampk激活剂和线粒体解偶联剂调节血糖水平的方法
JP2026526085A (ja) 2023-07-20 2026-08-05 ベタゲノン アーベー 代謝非柔軟性により誘発される心筋症の治療方法
CN121925257A (zh) 2023-08-03 2026-04-24 塔吉农有限责任公司 用pdk抑制剂4-氯-n-(2-(4-氯苄基)-3-氧代-2,3-二氢-1,2,4-噻二唑-5-基)苯甲酰胺治疗癌症
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Similar Documents

Publication Publication Date Title
EP4125896B1 (en) Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
US12440466B2 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
US6638530B1 (en) Benzamide formulation with histone deacetylase inhibitor activity
JP5698682B2 (ja) トライアシル−3−ヒドロキシフェニルアデノシン及びその血中脂肪の調節用途
TW201639571A (zh) 非酒精性脂肪肝病以及/或脂質營養不良症之治療方法
AU2006295440A1 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
CN1711085A (zh) 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物
JP7793614B2 (ja) チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのampkアゴニストとしての使用
JP6014623B2 (ja) 急性心不全の治療のための方法および組成物
KR20170061616A (ko) 피마살탄의 신규 염
US12453719B2 (en) Treatment method using a complex of angiotensin II receptor antagonist metabolite and NEP inhibitor
WO2011141419A1 (en) Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
JP2010529113A (ja) ピラゾロピリミジノン誘導体化合物を含む慢性心不全治療用医薬組成物
TWI659739B (zh) 便秘症之預防或治療藥
TW201206432A (en) Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof
JP2022541178A (ja) (s)-3-アミノ-6-メトキシ-n-(3,3,3-トリフルオロ-2-ヒドロキシ-2-メチルプロピル)-5-(トリフルオロメチル)ピコリンアミド製剤
US20260090994A1 (en) Tablet formulations
JP2006519881A5 (cg-RX-API-DMAC7.html)
WO2026098240A1 (zh) 萜品烯醇类化合物在制备治疗心脏疾病的药物中的应用
CN120988049A (zh) 一种含氟化合物及其制备方法和应用
JP2764287B2 (ja) 胃炎治療剤
WO2007123126A1 (ja) 慢性心不全における運動耐容能低下の改善剤
AU2021405273A1 (en) Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
EP3560490A1 (en) Oral ibuprofen preparation
JP2022510436A5 (cg-RX-API-DMAC7.html)